Navigation Links
Inovio Pharmaceuticals' Leadership for Life Sciences Recognized in the Philadelphia Region
Date:10/6/2011

very technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ab
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
2. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
3. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
4. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
5. Inovio Pharmaceuticals to Present at Investor Conferences
6. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
7. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
8. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
9. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
10. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
11. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014   BioNano Genomics announced today ... ability to collect human data at 30X depth, sufficient for ... This new capability was established and demonstrated for the IrysChip ... TM System and will be rolled out to ... will be showcasing this advancement at the American Society ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho Oncology, ... Ltd. ( Japan ), announced that ... Fast Track designation for TAS-102 (nonproprietary names: trifluridine ... under investigation for the treatment of refractory metastatic ... initiated a rolling NDA submission to the FDA. ...
(Date:10/20/2014)... Pharmaceutic Labs announces the opening of its ... NY for admixing, compounding, drug shortages and ... the FDA standards for safety and quality, using 21 ... The 10,000 square foot outsourcing facility was ... and quality control. The company will produce sterile and ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... NORTH BRUNSWICK, N.J., July 20, 2011 Artegraft, Inc. ... in the June 2011 issue of the Journal ... Bovine Carotid Artery vascular grafts (BCA) to cuffed ePTFE ... that the BCA graft had significantly higher primary and ...
... SUNNYVALE, Calif., July 20, 2011 Accuray ... premier radiation oncology company, will host a symposium ... oncology at the 2011 Joint American Association of ... (COMP) Meeting. The symposium—" Best Quality Assurance Programs ...
Cached Medicine Technology:Study Published in Journal of Vascular Surgery Confirms Superiority of Artegraft BCA to Cuffed ePTFE for Hemodialysis Access 2Accuray Hosts Symposium on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 2
(Date:10/20/2014)... 20, 2014 JZ Fitness, an independently ... corporate wellness programming, authorship, international lecturing and community wellness, ... announce the release of the JZ Fitness nutrition app, ... of coaching thousands of individuals on nutrition, Jenn Zerling ... does not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 National Teen Driver ... of the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ... in encouraging parents of teen drivers to talk to their ... road. , Motor vehicle crashes are the leading cause of ... drivers involved in fatal crashes, and 859 (42%) of those ...
(Date:10/20/2014)... 20, 2014 Punzoné , the first ... U.S., has a lot to celebrate this month. October marks ... the achievements and contributions of Americans of Italian heritage and ... and today it shares its favorite Italian cocktails and encourages ... Italy - even if it is only in a glass. ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
... ... ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) , ... , ...
... neurological disorder , WEDNESDAY, March 10 (HealthDay News) -- ... Charcot-Marie-Tooth syndrome, U.S. scientists have identified gene mutations associated ... nerves in the limbs, hands and feet. , The ... England Journal of Medicine , involved sequencing the complete ...
... finds only a third of those who get invasive procedure have ... walk into an emergency room complaining of chest pains, the odds ... a thin wire is snaked into your heart to determine whether ... you do have the invasive procedure, the odds are even higher ...
... hard-to-treat infestations, study shows, , WEDNESDAY, March 10 (HealthDay ... medication ivermectin is more effective than the standard treatment, ... study, published in the March 11 issue of the ... 95 percent of those treated with ivermectin were lice-free ...
... , ... ... ... Funds from Operations Modified (FFOM), excluding the non-recurring events summarized below, for fourth quarter 2009 was $7.9 million , or $0.16 per share and operating partnership unit. , ...
... Nurses United today announce that the Florida Hospital Patient Protection Act of 2010 has been filed in the state legislature by authors Rep. Oscar Braynon and Sen. ... ... ... ...
Cached Medicine News:Health News:U.S. Census Bureau Daily Feature for March 11 2Health News:Gene Mutations Identified for Charcot-Marie-Tooth Syndrome 2Health News:Doctors Turning to Cardiac Catheterization Too Quickly 2Health News:Doctors Turning to Cardiac Catheterization Too Quickly 3Health News:For Tough Head Lice, Pill Tops Lotion 2Health News:For Tough Head Lice, Pill Tops Lotion 3Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 2Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 3Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 4Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 5Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 6Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 7Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 8Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 9Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 10Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 11Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 12Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 13Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 14Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 15Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 16Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 17Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 18Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 19Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 20Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 21Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 22Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 23Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 24Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 25Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 26Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 27Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 28Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 29Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 30
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
Medicine Products: